Skip to main content
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Leukemia
The HARMONY Alliance: Novel Insights into Genomic Classification and Prognosis in Acute Myeloid Leukemia
Read More
Characteristics and Prognostic Effects of IDH Mutations Across the Age Spectrum in AML: A Collaborative Analysis
Read More
Effect of Early Blood Counts on Response and Overall SurvEffect of Early Blood Counts on Response and Overall Survival Following Glasdegib + LDAC in Newly Diagnosed AMLival Following Glasdegib + LDAC in Newly Diagnosed AML
Read More
Venetoclax plus Standard Intensive AML Induction/Consolidation with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML
Read More
Clinical Outcomes for Treatment-Naïve Patients with AML Ineligible for Intensive Chemotherapy Receiving Azacitidine or Decitabine
Read More
SAL-DaunoDouble Trial Interim Analysis: Single versus Double Induction with 7+3 for Patients with Newly Diagnosed AML
Read More
Prognostic Significance of Concomitant Gene Mutations in Intensively Treated Patients with IDH1/2 Mutated AML
Read More
Decitabine + Venetoclax versus Intensive Chemotherapy for Patients with Relapsed/Refractory AML: A Propensity Score–Matched Analysis
Read More
Escalated Dosing Schedules of CC-486 Effective for Patients Experiencing First AML Low Blast Count Relapse
Read More
Gilteritinib + Azacitidine or Azacitidine Alone in Patients with Newly Diagnosed, FLT3-Mutated Acute Myeloid Leukemia
Read More
1
2
3
4
5
6
Page 3 of 7
Results 21 - 30 of 64